Selective S1P1 Agonist Composition to Avoid Receptor Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune disorders such as multiple sclerosis, including fingolimod, act as non-selective S1P receptor agonists, leading to paradoxical receptor degradation and reduced lymphocyte egress, which can cause inflammation and tissue damage in the central nervous system.
Innovation Solution
Development of a novel sphingosine-1-phosphate receptor agonist, represented by Formula 1, which selectively activates S1P receptors to prevent lymphocyte infiltration and treat autoimmune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective S1P receptor agonists like fingolimod are used to treat autoimmune disorders, then lymphocyte egress is reduced and inflammation is suppressed, but receptor degradation occurs leading to paradoxical effects and potential tissue damage
Solution Approach 1:
The patent applies local quality by developing selective S1P1 receptor agonists with specific molecular structures (Formula 1 compounds) that target only the S1P1 receptor subtype rather than acting as non-selective agonists. This selectivity prevents the paradoxical receptor degradation effect while maintaining therapeutic efficacy in treating autoimmune disorders like multiple sclerosis.
Solution Approach 2:
The patent utilizes parameter changes by modifying the chemical structure of S1P1 receptor agonists through systematic variation of substituents (R1-R6 groups) to optimize binding affinity and selectivity. This structural parameter optimization ensures high-affinity binding to S1P1 receptor without triggering receptor degradation, thereby resolving the contradiction between therapeutic effect and harmful receptor degradation.
2Object-affected harmful factors
If S1P1 receptor agonists are used to prevent lymphocyte egress, then autoimmune inflammation is reduced, but lymphocyte recirculation is impaired
Solution Approach 1:
The patent applies partial action by using selective S1P1 receptor agonists that provide sufficient lymphocyte egress inhibition for therapeutic benefit without excessive activation that would completely block recirculation. The optimized compounds achieve a balanced effect where enough receptor activation occurs to prevent harmful lymphocyte infiltration, while preserving necessary recirculation function.
Data Source
AI summary
The present invention relates to a novel compound represented by Formula 1, functioning as a sphingosine-1-phosphate receptor agonist useful for treating autoimmune disorders, a preparation method therefor, a pharmaceutical composition containing the same as an active ingredient, and a use. The compound according to the present invention has an effect in extensive autoimmune diseases and chronic inflammatory diseases, including relapsing-remitting multiple sclerosis, and can also be used for treating or preventing immunoregulatory disorders.